Table 1.
Demographic and Clinical Characteristics by Therapy
| Oral Only (n = 21) | Prostanoid Only (n = 17) | Mixed Therapy (n = 7) | Vasodilator Responsive (n = 7) | p value | |
|---|---|---|---|---|---|
| Age (years) | 47.3±14.2 | 36.4±14.1 | 43.0±15.1 | 47.9±14.7 | 0.11 |
| Gender, % female | 88 | 76 | 100 | 86 | 0.55 |
| Functional Class (NYHA) | 2.1±0.6 | 2.1±1.0 | 2.0±0.8 | 1.9±0.9 | 0.94 |
| 6MWD (meters) | 387±111 | 370±117 | 321±136 | 377±93 | 0.59 |
| BMI (kg/m2) | 33.6±12.1 | 30.1±7.3 | 33.0±7.8 | 35.5±11.9 | 0.70 |
| Medical Therapy % (dose range) | n/a | ||||
| Epoprostenol (ng/kg/min) | 0 | 86 (11–30) | 57 (14.2–30) | 0 | |
| Treprostinil (IV or inhaled) (mg/kg/min) | 0 | 14 (12.5–100) | 43 (14–28) | 0 | |
| Ambrisentan (mg/day) | 18 (5) | 0 | 0 | 0 | |
| Bosentan (mg/day) | 35 (250) | 0 | 14 (250) | 0 | |
| Sildenafil (mg/day) | 47 (38–150) | 0 | 86 (60–150) | 0 | |
| Tadalafil (mg/day) | 12 (40) | 0 | 0 | 0 | |
| Amlodipine (mg/day) | 18 (5–10) | 0 | 0 | 42 (5–10) | |
| Diltiazem (mg/day) | 12 (180–360) | 0 | 0 | 29 (240–360) | |
| Nifedipine (mg/day) | 0 | 0 | 0 | 29 (30–120) | |
| Adjuvant Therapy | |||||
| Furosemide (mg/day) | 64 (20–160) | 66 (20–160) | 86 (20–160) | 71 (20–160) | 0.77 |
| Oxygen (L/min) | 6 (2) | 24 (2–4) | 29 (2–3) | 14 (2) | 0.42 |
| Warfarin (mg/day) | 47 (2.5–7.5) | 76 (1.25–11) | 49 (4–7.5) | 49 (5–9) | 0.17 |
BMI = body mass index; IV = intravenous; WHO = World Health Organization.